Related Experiment Video

Updated: Jun 13, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Remission in juvenile idiopathic arthritis: current facts

Susan Shenoi1, Carol A Wallace

  • 1Division of Pediatric Rheumatology, University of Washington School of Medicine and Seattle Children's Hospital, 4800 Sand Point Way NE, Seattle, WA 98105, USA.

Current Rheumatology Reports
|April 29, 2010
PubMed

Insights

Juvenile idiopathic arthritis (JIA) remission is challenging to achieve. New criteria show low remission rates, especially for rheumatoid factor-positive polyarticular JIA, highlighting the need for improved JIA treatment strategies.

Area of Science:

  • Pediatric Rheumatology
  • Immunology
  • Clinical Pediatrics

Background:

  • Juvenile idiopathic arthritis (JIA) is the most prevalent chronic inflammatory arthritis in children.
  • Current treatments often fail to prevent long-term disease activity and joint damage.
  • Achieving remission is crucial for optimal physical function and normal childhood development.

Purpose of the Study:

  • To review recently developed preliminary criteria for inactive disease and remission in JIA.
  • To evaluate the rates of remission achievement based on these new definitions.
  • To discuss therapeutic strategies aimed at achieving remission in JIA.

Main Methods:

  • Review of recent studies utilizing new preliminary criteria for JIA remission.
  • Analysis of remission rates across different JIA subtypes.
  • Discussion of therapeutic approaches for JIA management.

Main Results:

  • Modest rates of remission achievement were observed using the new criteria.
  • Children with persistent oligoarticular JIA showed higher rates of remission.
  • Rheumatoid factor-positive polyarticular JIA patients had the lowest likelihood of achieving remission.

Conclusions:

  • Current remission rates in JIA remain low, even with advanced therapies.
  • New criteria highlight disparities in remission achievement among JIA subtypes.
  • Further research into effective therapeutic strategies is essential for improving JIA outcomes.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...